おかえりなさい
Click “ログイン” to agree to Cointime’s 利用規約 and acknowledge that Cointime’s プライバシーポリシー applies to you.
アカウント登録
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">利用規約</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">プライバシーポリシー</a> applies to you.
siteでログインする
siteで登録する
あなたのメールアドレス
受信トレイを確認する
Click the link we sent to to sign in.
Click the link we sent to to sign up.
ActoGeniX
company
About
A biopharmaceutical company, focused on the development and commercialization of a new generation of biological drugs.
- 251 - 500
Details
- Last Funding Type
- Series Unknown
- Last Funding Money Raised
- €20M
- Industries
- Biopharma,Biotechnology,Clinical Trials,Pharmaceutical
- Founded date
- Jan 1, 2006
- Number Of Employee
- 251 - 500
- Operating Status
- Active
ActoGeniX is a biopharmaceutical company focused on the development and commercialization of a range of biological drugs.ActoGeniX was founded by Bernard Coulie and Mark Vaeck in 2006 and is based in Zwijnaarde, Belgium.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
€33.50M
ActoGeniX has raised a total of
€33.50M
in funding over 2 rounds. Their latest funding was raised on
Feb 11, 2009 from a Private Equity（PE） round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Feb 11, 2009 | Private Equity（PE） | €13.50M | 2 | — | — | Detail |
| Feb 8, 2007 | Series Unknown | €20M | 2 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
2
ActoGeniX is funded by 2 investors.
Biotech Fund Flanders
and Baekeland Funds
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Biotech Fund Flanders
|
— | Private Equity（PE） |
Baekeland Funds
|
— | Private Equity（PE） |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
